Search - tctmd.com

Displaying 681 - 700 of 1103

Sort: Relevancy | Date

News Daily News

Uptick Seen in Medication Adherence Among Hypertensive Patients Using Mobile App

Michael O'Riordan

April 16, 2018

News Daily News

Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say

Michael O'Riordan

April 09, 2018

News Daily News

Costs of Atherosclerotic CVD Cripple Low-Income Families, Even With Insurance

Shelley Wood

April 06, 2018

News Daily News

One in Three Cardiac Patients Use Complementary Health, Often Unbeknownst to Their Doctors

Yael L. Maxwell

April 05, 2018

News Daily News

Respiratory Syncytial Virus Linked With Cardiovascular Complications

Michael O'Riordan

April 04, 2018

News Daily News

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

Shelley Wood

March 29, 2018

News Daily News

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Yael L. Maxwell

March 28, 2018

Podcast Heart Sounds

Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA

Caitlin E. Cox

March 26, 2018

News Daily News

European Regulators Nix Portola’s Factor Xa Inhibitor Betrixaban

Todd Neale

March 23, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Perioperative Beta-blockade for Noncardiac Surgery Increases Death, Stroke at 1 Year

Yael L. Maxwell

March 15, 2018

News Conference News ACC 2018

Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension

Michael O'Riordan

March 15, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

Presentation ACC 2018

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Presenter: Brendan M. Everett

March 12, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

Presentation ACC 2018

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Presenter: Philippe Gabriel Steg

March 10, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Daily News

Bempedoic Acid Phase III Trial Meets Primary Endpoint for Cutting LDL Cholesterol

Yael L. Maxwell

March 08, 2018

News Daily News

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Michael O'Riordan

March 06, 2018

Advertisement

Uptick Seen in Medication Adherence Among Hypertensive Patients Using Mobile App

Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say

Costs of Atherosclerotic CVD Cripple Low-Income Families, Even With Insurance

One in Three Cardiac Patients Use Complementary Health, Often Unbeknownst to Their Doctors

Respiratory Syncytial Virus Linked With Cardiovascular Complications

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Top Stories in Cardiology, March 2018

Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA

European Regulators Nix Portola’s Factor Xa Inhibitor Betrixaban

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Perioperative Beta-blockade for Noncardiac Surgery Increases Death, Stroke at 1 Year

Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Bempedoic Acid Phase III Trial Meets Primary Endpoint for Cutting LDL Cholesterol

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content